Cargando…

Metabolomic applied to omalizumab effect in severe asthmatics – a preliminary result

Detalles Bibliográficos
Autores principales:	Loureiro, Cláudia Chaves, Caldeira, M, Rocha, Sílvia, Todo-Bom, Ana, Loureiro, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647293/ http://dx.doi.org/10.1186/2045-7022-3-S1-P26

Ejemplares similares

Eosinophilic esophagitis: a matter of flavoring
por: Gomes, Raquel, et al.
Publicado: (2015)

P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children
por: Spangenberg, Katrine B, et al.
Publicado: (2014)

Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics
por: Sintobin, Ina, et al.
Publicado: (2015)

Omalizumab as successful treatment option in severe peanut allergy
por: Dehlink, E, et al.
Publicado: (2013)

P23 - Boy with severe atopic dermatitis treated with omalizumab
por: Stefanaki, Evangelia, et al.
Publicado: (2014)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Severe food allergy in children. Omalizumab as an alternative treatment to elimination diet
por: Pena Peloche, María, et al.
Publicado: (2011)

Metabolic Phenotypes in Asthmatic Adults: Relationship with Inflammatory and Clinical Phenotypes and Prognostic Implications
por: Santos, Adalberto, et al.
Publicado: (2021)

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2015)

Good outcomes of pregnancy in two cases of women treated with omalizumab due to the severe asthma
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2013)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

Positive end-expiratory pressure can increase brain tissue oxygen pressure in hypoxemic severe traumatic brain injury patients
por: Nemer, SN, et al.
Publicado: (2011)

Pretreatment by omalizumab allows allergen-specific immunotherapy in children and young adult with severe allergic asthma
por: Lambert, Nathalie, et al.
Publicado: (2015)

Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics
por: Yan, Huacheng, et al.
Publicado: (2023)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Poster 1002: Galectin-3 as predictive biomarker of airways remodeling modulation in omalizumab treated severe asthma patients
por: Mauri, Pierluigi, et al.
Publicado: (2014)

P98 - Gluten allergy
por: Barrosa Maia, Estefânia, et al.
Publicado: (2014)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
por: Gonzalez-Diaz, Sandra Nora, et al.
Publicado: (2014)

ACE polymorphism in asthmatic patients
por: Cortez, Margarida, et al.
Publicado: (2013)

P25 - Hypersensitivity/adverse reactions to antituberculosis drugs – a case report
por: Barrosa Maia, Estefânia, et al.
Publicado: (2014)

Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

Influence of physical activity in asthmatic children
por: Tancredi, Giancarlo, et al.
Publicado: (2013)

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
por: Jung, Jae-Woo, et al.
Publicado: (2021)

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
por: Jung, Jae-Woo, et al.
Publicado: (2021)

P67 - Mothers restrict physical activity for children and teens asthmatics
por: Correia Junior, Marco, et al.
Publicado: (2014)

Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014)

Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab
por: De Schryver, Els, et al.
Publicado: (2015)

PD11 - Omalizumab in children: experience in the Immunoallergology Department
por: Aguiar, Rita, et al.
Publicado: (2014)

Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients
por: Nayci, Sibel, et al.
Publicado: (2015)

Oxford Miniature Vaporiser for halothane in ventilated asthmatics
por: Nagappan, R, et al.
Publicado: (2006)

Applying a new weaning index in ICU older patients
por: Azeredo, LM, et al.
Publicado: (2011)

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010)

Efficacy and safety of omalizumab treatment to facilitate successful oral desensitisation in high-risk milk-allergic patients
por: Aguiar, Rita, et al.
Publicado: (2015)

Texture analysis applied to full-field digital mammography: ability to discriminate between invasive ductal and invasive lobular breast cancer - preliminary results
por: Mayerhoefer, M, et al.
Publicado: (2010)

Hemicellulose from cane bagasse as assessed by OLIMP MALDI-TOF/MS
por: Lopes, Francis, et al.
Publicado: (2014)

Food hypersensitivity among asthmatic children – single center experience
por: Al-Ani, SS, et al.
Publicado: (2013)

The prevalence of IgE-dependent food allergy in asthmatic children
por: Krogulska, A, et al.
Publicado: (2013)

The role of type 1 angiotensin 2 receptor polymorphism in asthmatic patients
por: Cortez, Margarida, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ml2lnktn6e5ms852an1galkqm0